IP Library › Granted Patent US 12,371,489
Granted Patent B2
US 12,371,489 · App. 17/321,629 · Granted Jul 29, 2025

Car based immunotherapy

Inventors: Lung-Ji Chang (Gainesville, FL); Jan S. Moreb (Gainesville, FL)
Assignee: University of Florida Research Foundation, Incorporated
C07K16/2803A61K40/11A61K40/31A61K40/4211C07K14/7051C07K14/70521C07K14/70578C07K16/30C12N5/0638A61K2039/505C07K2317/622C07K2319/02C07K2319/03C07K2319/30C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,371,489
App. No.
17/321,629
Granted
Jul 29, 2025
Kind
B2
Abstract

The disclosure provides chimeric antigen receptors (CARs), T cells comprising such CARs, nucleic acids that encode such CARS, and methods of use thereof, e.g., to treat cancer such as B cell malignancies.

Claims (4)

1. A method for stimulating a T cell-mediated immune response to a target cell population or tissue in a mammal, the method comprising

administering to the mammal an effective amount of a T cell comprising an exogenous nucleic acid that expresses a chimeric antigen receptor (CAR), the CAR comprising an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the costimulatory signaling region consists of a CD28 signaling domain, a CD137 signaling domain and a CD27 signaling domain; and wherein the antigen binding domain is selected to specifically recognize the target cell population or tissue.

2. The method of claim 1 , wherein the T cell is an autologous T cell.

3. The method of claim 1 , wherein the target cell population or tissue expresses a tumor antigen selected from the group consisting of CD19, CD20, CD22, ROR1, mesothelin, CD33/IL3Ra, c-Met, PSMA, Glycolipid F77, EGFRvIII, GD-2, NY-ESO-1 TCR, and MAGE A3 TCR.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2021
From: CHANG, LUNG-JI; MOREB, JAN S.
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
Reel/Frame 057280/0622 →
Continuity (3)
Division 15312370
Provisional Application 62002603 · May 23, 2014
Related Publication 20210277114A1 · Sep 9, 2021
References Cited (88)
US 9089520B2 · Brenner · 2015 [cited by applicant]
US 10117932B2 · Shultz et al. · 2018 [cited by applicant]
US 10647778B2 · Chang · 2020 [cited by applicant]
US 11041021B2 · Chang et al. · 2021 [cited by applicant]
US 11248058B2 · Chang · 2022 [cited by applicant]
US 11634498B2 · Rivkees et al. · 2023 [cited by applicant]
US 20040043401A1 · Sadelain et al. · 2004 [cited by applicant]
US 20050113564A1 · Campana et al. · 2005 [cited by applicant]
US 20130280220A1 · Ahmed et al. · 2013 [cited by applicant]
US 20140301993A1 · Powell, Jr. et al. · 2014 [cited by applicant]
US 20140322183A1 · Milone et al. · 2014 [cited by applicant]
US 20150023937A1 · Vera Valdes et al. · 2015 [cited by applicant]
US 20150118252A1 · Ho et al. · 2015 [cited by applicant]
US 20150329640A1 · Finer · 2015 [cited by applicant]
US 20160046724A1 · Brogdon et al. · 2016 [cited by applicant]
US 20160058857A1 · Spencer et al. · 2016 [cited by applicant]
US 20170137515A1 · Chang et al. · 2017 [cited by applicant]
US 20170226216A1 · Morgan et al. · 2017 [cited by applicant]
US 20180022815A1 · Chang · 2018 [cited by applicant]
US 20180142034A1 · Chang · 2018 [cited by applicant]
US 20190153109A1 · Rivkees et al. · 2019 [cited by applicant]
US 20220135699A1 · Chang et al. · 2022 [cited by applicant]
US 20230295319A1 · Rivkees et al. · 2023 [cited by applicant]
WO WO2010095031A2 · 2010 [cited by applicant]
WO WO2011146862A1 · 2011 [cited by applicant]
WO WO2012033885A1 · 2012 [cited by applicant]
WO WO2012058460A2 · 2012 [cited by applicant]
WO WO2012079000A1 · 2012 [cited by applicant]
WO WO2013074916A1 · 2013 [cited by applicant]
WO WO2013123061A1 · 2013 [cited by applicant]
WO WO2013126729A1 · 2013 [cited by applicant]
WO WO2014039523A1 · 2014 [cited by applicant]
WO WO2014055771A1 · 2014 [cited by applicant]
WO WO2014124143A1 · 2014 [cited by applicant]
WO WO2014055657A1 · 2014 [cited by applicant]
WO WO2014165707A2 · 2014 [cited by applicant]
WO WO2015142675A2 · 2015 [cited by applicant]
WO WO2015179801A1 · 2015 [cited by applicant]
WO WO2016130598A1 · 2016 [cited by applicant]
Ormandy et al. Genetic engineering of animals: Ethical issues, including welfare concerns. Can Vet J. May 2011;52(5):544-50. (Year: 2011). [cited by examiner]
Carlson et al. Targeting DNA With Fingers and TALENs. Mol Ther Nucleic Acids. Jan. 24, 2012;1(1):e3. (Year: 2012). [cited by examiner]
Wang et al. One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering. Cell. May 9, 2013;153(4):910-8. Epub May 2, 2013. (Year: 2013). [cited by examiner]
Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th edition. New York: Garland Science; 2002. Chapter 22, Histology: The Lives and Deaths of Cells in Tissues. Available from: https://www.ncbi.nlm.ni… [cited by examiner]
Cascalho et al. The Immunological Barrier to Xenotransplantation. Immunity. Apr. 2001;14(4):437-46 (Year: 2001). [cited by examiner]
Choudhery et al. CAR-T-Cell-Based Cancer Immunotherapies: Potentials, Limitations, and Future Prospects. J Clin Med. May 29, 2024;13(11):3202. (Year: 2024). [cited by examiner]
Supplementary European Search Report mailed Jun. 12, 2018 for Application No. EP 16749750.2. [cited by applicant]
International Search Report and Written Opinion mailed May 20, 2016 for Application No. PCT/US2016/017219. [cited by applicant]
International Preliminary Report on Patentability mailed Aug. 24, 2017 for Application No. PCT/US2016/017219. [cited by applicant]
Partial Supplementary European Search Report mailed Jul. 27, 2018 for Application No. EP 16753166.4. [cited by applicant]
Supplementary European Search Report mailed Nov. 6, 2018 for Application No. EP 16753166.4. [cited by applicant]
International Search Report and Written Opinion mailed Jun. 17, 2016 for Application No. PCT/US2016/018716. [cited by applicant]
International Preliminary Report on Patentability mailed Aug. 31, 2017 for Application No. PCT/US2016/018716. [cited by applicant]
International Search Report and Written Opinion mailed Sep. 14, 2015 for Application No. PCT/US2015/032245. [cited by applicant]
International Preliminary Report on Patentability mailed Dec. 8, 2016 for Application No. PCT/US2015/032245. [cited by applicant]
International Search Report and Written Opinion mailed Sep. 6, 2017 for Application No. PCT/US2017/030279. [cited by applicant]
International Preliminary Report on Patentability mailed Nov. 8, 2018 for Application No. PCT/US2017/030279. [cited by applicant]
Callahan et al., At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol. Jul. 2013;94(1):41-53. doi: 10.1189/jlb.1212631. Epub May 10, 2013. [cited by applicant]
Di Stasi et al., Inducible Apoptosis as a Safety Switch for Adopitce Cell Therapy. The New England Journal of Medicine. Nov. 3, 2011;365(18):1673-83. [cited by applicant]
Gargett et al., The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Frontiers in Pharmacology. Oct. 2014;5:1-7. [cited by applicant]
Genbank Submission; “AAAT18_RS09785 hypothetical protein [ [cited by applicant]
Genbank Submission; NIH/NCBI, Accession No. NP_001183.2: “TNFRSF17 TNF receptor superfamily member 17[ [cited by applicant]
Genbank Submission; NIH/NCBI, Accession No. NP_002988.2: “syndecan-1 precursor [ [cited by applicant]
Gill et al., CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road. Expert Opin Biol Ther. Jan. 2014;14(1):37-49. doi: 10.1517/14712598.2014.860442. Epub Nov. 21, 2013. [cited by applicant]
Heczey et al., Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood. Oct. 30, 2014;124(18):2824-33. doi: 10.1182/blood-2013-11-541235. Epub Jul. … [cited by applicant]
Highfill et al., Anti-PD1 Therapy for Pediatric Sarcomas. Retrieved from the Internet. http://sarcomahelp.org/research/immuntherapy-pediatric-sarcomas.html#tpm2_1. May 10, 2016. [cited by applicant]
Lee et al., The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res. May 15, 2012;18(10):2780-90. doi: 10.1158/1078-0432.CCR-11-1920. [cited by applicant]
Novak et al., Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. Jan. 2004;103(2):689-694. [cited by applicant]
Prosser et al., Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Mol Immunol. Jul. 2012;51(3-4):263-72. doi: 10.1016/j.molimm.2012.03.023. Epub Apr. 11, … [cited by applicant]
Rappl et al., The CD3-Zeta Chimeric Antigen Receptor Overcomes TCR Hypo-Responsiveness of Human Terminal LateStage T Cells. PLoS One. 2012;7(1):e30713:1-10. [cited by applicant]
Sadelain et al., The Basic Principles of Chimeric Antigen Receptor Design. Cancer Discovery. Apr. 2013;3(4):388-98. [cited by applicant]
Sherbenou et al., The development of potential antibody-based therapies for myeloma. Blood Rev. Mar. 2015;29(2):81-91. doi: 10.1016/j.blre.2014.09.011. Epub Sep. 28, 2014. [cited by applicant]
Song et al., CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood. Jan. 19, 2012;119(3):696-706. doi: 10.1182/blood-2011-03-344275. Epub Nov. 23, 2011. [cited by applicant]
Straathof et al., An inducible caspase 9 safety switch for T-cell therapy. Blood. Jun. 1, 2005;105(11):4247-54. doi: 10.1182/blood-2004-11-4564. Epub Feb. 22, 2005. [cited by applicant]
Wu et al., The IL-15 receptor α chain cytoplasmic domain is critical for normal IL-15R α function but is not required for trans-presentation. Blood. Sep. 2008;112(12):4411-4419. [cited by applicant]
U.S. Appl. No. 17/575,762, filed Jan. 14, 2022, Chang. [cited by applicant]
U.S. Appl. No. 16/097,437, filed Oct. 29, 2018, Rivkees et al. [cited by applicant]
EP 16749750.2, Jun. 12, 2018, Supplementary European Search Report. [cited by applicant]
PCT/US2016/017219, May 20, 2016, International Search Report and Written Opinion. [cited by applicant]
PCT/US2016/017219, Aug. 24, 2017, International Preliminary Report on Patentability. [cited by applicant]
EP 16753166.4, Jul. 27, 2018, Partial Supplementary European Search Report. [cited by applicant]
EP 16753166.4, Nov. 6, 2018, Supplementary European Search Report. [cited by applicant]
PCT/US2016/018716, Jun. 17, 2016, International Search Report and Written Opinion. [cited by applicant]
PCT/US2016/018716, Aug. 31, 2017, International Preliminary Report on Patentability. [cited by applicant]
PCT/US2015/032245, Sep. 14, 2015, International Search Report and Written Opinion. [cited by applicant]
PCT/US2015/032245, Dec. 8, 2016, International Preliminary Report on Patentability. [cited by applicant]
PCT/US2017/030279, Sep. 6, 2017, International Search Report and Written Opinion. [cited by applicant]
PCT/US2017/030279, Nov. 8, 2018, International Preliminary Report on Patentability. [cited by applicant]
Hoyos et al., Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. Jun. 2010;24(6):1160-70. doi: 10.1038/leu.2010.75. Epub … [cited by applicant]